Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Jul
02
Today In Oncology
Metastatic Castration-Resistant Prostate Cancer Comparison of Second-Line Regimens
AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative
HER3-DXd in NSCLC Without EGFR-Activating Mutations
Survey Shows Inaccuracies in US Perceptions of Testicular Cancer
utDNA May Help to Personalize Bladder Cancer Treatment
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo